Hipro Biotechnology Co.,Ltd
Hipro Biotechnology Co.,Ltd
Contact Us

Vascular Inflammation, Hscrp And Lp-pla2 Can Tell

The heart is the blood supply center of the human body, and the coronary artery is the blood vessel that supplies the heart muscle especially. Coronary atherosclerosis is the most common coronary artery lesion and the pathological basis of common cardiovascular diseases.


HsCRP & Lp-PLA2



Prevention and treatment of cardiovascular disease is urgent


According to ‘China Cardiovascular Health and Disease Report 2019’, overall, the prevalence and mortality of cardiovascular diseases in China are still on the rise. The total number of patients with cardiovascular diseases is estimated to be 330 million, including 13 million with stroke, 11 million with coronary heart disease, 5 million with pulmonary heart disease, 8.9 million with heart failure, 2.5 million with rheumatic heart disease, 2 million with congenital heart disease, 45.3 million with lower limb artery disease and 245 million with hypertension. At present, cardiovascular disease is the leading cause of death among urban and rural residents, accounting for 45.91% in rural areas and 43.56% in urban areas. The increasing burden of cardiovascular diseases in China has become a major public health problem, and it is urgent to prevent and cure cardiovascular diseases.



Inflammation is also an accomplice of coronary sclerosis


Referring to the causes of coronary sclerosis, you may be the first time think of hyperlipidemia, hypertension, diabetes, obesity, smoking and age, gender, etc., and lack of exercise, eat less or don't eat enough fruits and vegetables, spirit and social factors, hormonal, and even include genetic factors, such as. Actually, everybody often ignores the inflammation, it is also one of the accomplices of lead to hardening of the arteries, and there is often gang activity between the various factors.

Inflammation participates in the occurrence and development of atherosclerosis, affects the structure of vascular endothelium, promotes the pathogenesis of atherosclerosis, accelerates the instability and even rupture of arterial plaques, and is an important factor causing various malignant events in coronary arteries.


HsCRP & Lp-PLA2



HsCRP and Lp-PLA2 can indicate vascular inflammation


As a common inflammatory marker, HsCRP is involved in the inflammatory response of the body and plays a role in causing atherosclerosis.

A. Risk predictors of coronary artery disease

The detection of the HsCRP level can reflect the degree of injury of coronary endothelial cells and whether the atherosclerotic plaque is stable.

B. Early warning indicators of cardiovascular risk events

The level of hs-CRP is positively correlated with cardiovascular risk. When the level of HsCRP is high, the cardiovascular risk will significantly increase, otherwise, the risk is relatively low.

C. Evaluate the efficacy and prognosis of CHD

HsCRP has become a reference index for the prevention and treatment of coronary heart disease.


HsCRP & Lp-PLA2


Lp-PLA2 is a novel inflammatory molecule related to atherosclerosis and ischemic cardio-cerebrovascular diseases. It can hydrolyze OX-LDL to produce oxidized free fatty acids and lytic lecithin, both of which are pro-inflammatory mediators, induce endothelial dysfunction, and promote smooth muscle cell apoptosis, thus playing a pro-atherosclerosis role.


A. It is a strong vascular specific inflammatory factor

Lp-PLA2 has a strong pro-inflammatory and atherosclerotic effect and is also a strong specific indicator to evaluate vascular inflammation.

B. Risk factors for atherosclerotic plaque

High levels of Lp-PLA2 indicate that atherosclerotic plaques are more prone to rupture and the risk of cardiovascular and cerebrovascular malignant events is increased.

C. Independent prediction of cardio-cerebrovascular embolic diseases

Dynamic monitoring of Lp-PLA2 changes has important guiding significance for the occurrence and therapeutic evaluation of cardio-cerebrovascular embolic diseases.


HsCRP & Lp-PLA2


News Related to Hipro Point-of-care Products
Products